Loading
Latest filing published 25 Sept 2026 for Ascelia Pharma AB, €1,388. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Andreas Linderoth Norlin is a declared insider of Ascelia Pharma AB (board member), with filings sourced from Finansinspektionen. We count 3 filings; the first trade dates from 25 November 2025 and the latest from 25 September 2026.
No open-market sale appears; the market trades are 2 purchases worth €3,208. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Other entries cover 1 share grant. So far in 2026, the count stands at 2 purchases and no sales.
The record was last updated on 25 September 2026 with an open-market purchase (€1,388) in Ascelia Pharma AB. Half of the filings or more reach the Finansinspektionen feed on the day of the trade. The legal deadline for notifying a trade is three business days (MAR article 19). Every figure here comes from the filings published by Finansinspektionen and describes the past, not future prices; it is not investment advice.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
3 of 3 declarations